{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0004980,73,MONDO:0004980,158,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0004980","source":"MONDO:0004980|atopic eczema","targets":["NCT00106496|A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00117377|Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00119158|Combination Therapy for Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00120302|Quality of Life Study in Adults With Facial Eczema|COMPLETED|PHASE4|INTERVENTIONAL","NCT00121316|Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00121381|Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00124709|Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification|TERMINATED|PHASE4|INTERVENTIONAL","NCT00130364|Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00139581|Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects|COMPLETED|PHASE4|INTERVENTIONAL","NCT00150059|Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00179959|The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00180141|Elidel-Study: Elidel in Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00185510|Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00236106|Short Term Growth in Children With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00367016|Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00367393|Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00368719|Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00445081|Prednisolone vs. Ciclosporine in Severe Atopic Eczema|COMPLETED|PHASE4|INTERVENTIONAL","NCT00460083|Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00484003|A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00509990|Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting|COMPLETED|PHASE4|INTERVENTIONAL","NCT00510003|Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old|COMPLETED|PHASE4|INTERVENTIONAL","NCT00521131|Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites|COMPLETED|PHASE4|INTERVENTIONAL","NCT00546000|Cutivate Lotion HPA Axis Pediatric Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT00557284|Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens|COMPLETED|PHASE4|INTERVENTIONAL","NCT00559546|Montelukast as a Controller of Atopic Syndrome|COMPLETED|PHASE4|INTERVENTIONAL","NCT00616538|Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00654355|Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit|COMPLETED|PHASE4|INTERVENTIONAL","NCT00666159|Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00666302|A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00667056|Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00667160|Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00671528|Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)|TERMINATED|PHASE4|INTERVENTIONAL","NCT00673725|Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00689832|Protopic Ointment in Children Atopic Eczema|COMPLETED|PHASE4|INTERVENTIONAL","NCT00690105|Protopic Ointment in Adult Atopic Eczema of the Face|COMPLETED|PHASE4|INTERVENTIONAL","NCT00690833|Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00693693|Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00771121|Effect of Moisturizing Creams on Skin Barrier Function|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00810862|Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children|TERMINATED|PHASE4|INTERVENTIONAL","NCT00819507|VANOS Cream and Skin Barrier Function|COMPLETED|PHASE4|INTERVENTIONAL","NCT00822783|Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00828412|Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00832585|Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00846235|Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00871208|Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00878670|Investigation of Efficacy and Safety of EPOGAM|COMPLETED|PHASE4|INTERVENTIONAL","NCT00884325|Management of Pruritus With Xyzal in Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00925730|Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion|COMPLETED|PHASE4|INTERVENTIONAL","NCT01049243|A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01063218|Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application|COMPLETED|PHASE4|INTERVENTIONAL","NCT01064947|Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01065714|A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01077882|Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01093469|Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01137032|Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population|COMPLETED|PHASE4|INTERVENTIONAL","NCT01177566|Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.|COMPLETED|PHASE4|INTERVENTIONAL","NCT01202149|Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01231854|Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.|TERMINATED|PHASE4|INTERVENTIONAL","NCT01781663|Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01782729|An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01828879|An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT02300701|Role of Anti-IgE in Severe Childhood Eczema|COMPLETED|PHASE4|INTERVENTIONAL","NCT02317276|A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal|TERMINATED|PHASE4|INTERVENTIONAL","NCT02519556|Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children|COMPLETED|PHASE4|INTERVENTIONAL","NCT02534467|Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?|COMPLETED|PHASE4|INTERVENTIONAL","NCT02601222|Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02680301|Topical Steroid Formulation and Wet Wraps|COMPLETED|PHASE4|INTERVENTIONAL","NCT02732314|Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03050294|Evaluating Treatment Resistant Dermatitis TaroIIR|COMPLETED|PHASE4|INTERVENTIONAL","NCT03257215|Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? the D-Vex Pilot Study|TERMINATED|PHASE4|INTERVENTIONAL","NCT03293030|Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03356977|A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03388866|Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03389893|Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis|TERMINATED|PHASE4|INTERVENTIONAL","NCT03406117|A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests|COMPLETED|PHASE4|INTERVENTIONAL","NCT03461302|Efficacy of Topical Coal Tar in Children With Atopic Dermatitis|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03539601|A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD|TERMINATED|PHASE4|INTERVENTIONAL","NCT03667014|The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT03710044|Investigation of Flare and Remission in Subjects With Atopic Dermatitis|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT03832010|Steroid-reducing Effects of Crisaborole|COMPLETED|PHASE4|INTERVENTIONAL","NCT03868098|Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT04016025|A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers|COMPLETED|PHASE4|INTERVENTIONAL","NCT04023084|Response of Children With Atopic Dermatitis (Eczema) to Eucrisa|COMPLETED|PHASE4|INTERVENTIONAL","NCT04033367|SAR231893-LPS15497- Dupilumab Effect on Sleep in AD Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT04114097|The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover|COMPLETED|PHASE4|INTERVENTIONAL","NCT04214197|Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04271007|Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates|COMPLETED|PHASE4|INTERVENTIONAL","NCT04358224|The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment|COMPLETED|PHASE4|INTERVENTIONAL","NCT04447417|Dupilumab Skin Barrier Function Study in Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT04520308|An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04718870|Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT04823130|Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis|COMPLETED|PHASE4|INTERVENTIONAL","NCT04895423|Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04900948|Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life|COMPLETED|PHASE4|INTERVENTIONAL","NCT04938700|Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05042258|Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis|RECRUITING|PHASE4|INTERVENTIONAL","NCT05200403|Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis|TERMINATED|PHASE4|INTERVENTIONAL","NCT05265234|Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05268107|Ethnic Differences in Mechanisms of Action of Dupilumab|RECRUITING|PHASE4|INTERVENTIONAL"]}]}